VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

BRIDGEWATER, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended September 30, 2025, and provided a business update.

Read more at globenewswire.com